SG10201709670XA - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor - Google Patents
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitorInfo
- Publication number
- SG10201709670XA SG10201709670XA SG10201709670XA SG10201709670XA SG10201709670XA SG 10201709670X A SG10201709670X A SG 10201709670XA SG 10201709670X A SG10201709670X A SG 10201709670XA SG 10201709670X A SG10201709670X A SG 10201709670XA SG 10201709670X A SG10201709670X A SG 10201709670XA
- Authority
- SG
- Singapore
- Prior art keywords
- administering
- inhibitor
- methods
- specific immunotherapy
- treating allergy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361830919P | 2013-06-04 | 2013-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201709670XA true SG10201709670XA (en) | 2018-01-30 |
Family
ID=51023185
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913835XA SG10201913835XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
SG11201509044QA SG11201509044QA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
SG10201709670XA SG10201709670XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913835XA SG10201913835XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
SG11201509044QA SG11201509044QA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
Country Status (26)
Country | Link |
---|---|
US (5) | US10392439B2 (en) |
EP (2) | EP3004166B1 (en) |
JP (5) | JP6499167B2 (en) |
KR (3) | KR102580468B1 (en) |
CN (1) | CN105377894A (en) |
AU (3) | AU2014275094C1 (en) |
CA (1) | CA2914203C (en) |
CY (1) | CY1124095T1 (en) |
DK (1) | DK3004166T3 (en) |
ES (1) | ES2767080T3 (en) |
HK (1) | HK1216898A1 (en) |
HR (1) | HRP20200185T1 (en) |
HU (1) | HUE048655T2 (en) |
IL (2) | IL242456B (en) |
LT (1) | LT3004166T (en) |
MX (2) | MX2015016473A (en) |
NZ (1) | NZ630183A (en) |
PL (1) | PL3004166T3 (en) |
PT (1) | PT3004166T (en) |
RS (1) | RS59883B1 (en) |
RU (1) | RU2679920C2 (en) |
SG (3) | SG10201913835XA (en) |
SI (1) | SI3004166T1 (en) |
TW (3) | TWI755763B (en) |
WO (1) | WO2014197470A1 (en) |
ZA (1) | ZA201508174B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2701093T3 (en) | 2012-08-21 | 2019-02-20 | Sanofi Biotechnology | Methods to treat or prevent asthma by administering an IL-4R antagonist |
TWI755763B (en) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
CA2915839A1 (en) | 2013-06-21 | 2014-12-24 | Leda MANNENT | Methods for treating nasal polyposis by administering an il-4r antagonist |
TWI634900B (en) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
JP6861630B2 (en) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist |
CA3232651A1 (en) * | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
EP3390451A1 (en) * | 2015-12-18 | 2018-10-24 | Intervet International B.V. | Caninized human antibodies to human and canine il-4ralpha |
AU2017220184B2 (en) | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
EP3506931A1 (en) * | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
CA3037154A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
CN109923411B (en) | 2016-10-25 | 2022-05-31 | 里珍纳龙药品有限公司 | Method and system for chromatographic data analysis |
TWI784988B (en) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
PT3515465T (en) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
EP3703818B1 (en) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
MX2020005699A (en) * | 2017-12-13 | 2020-10-16 | Regeneron Pharma | Devices and systems for chromatography column bed support management and related methods. |
RU2758092C1 (en) * | 2018-02-01 | 2021-10-26 | Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. | ANTIBODY TO IL-4Rα AND APPLICATION THEREOF |
CN108373505B (en) | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | Anti- IL-4R antibody and application thereof |
KR20210018808A (en) * | 2018-04-25 | 2021-02-18 | 키닉사 파마슈티컬스, 리미티드 | Treatment of skin diseases or disorders by delivery of anti-OSMRß antibodies |
TWI814812B (en) | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | Methods for evaluating suitability of a biochemical filter |
KR20210010518A (en) | 2018-05-13 | 2021-01-27 | 리제너론 파아마슈티컬스, 인크. | How to treat atopic dermatitis by administering an IL-4R inhibitor |
TW202005694A (en) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
CN113164593A (en) * | 2018-09-14 | 2021-07-23 | 金德雷德生物科学股份有限公司 | Veterinary anti-IL 4 receptor antibodies |
EP3878868A4 (en) * | 2018-11-09 | 2022-07-27 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
CN111494625B (en) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | Pharmaceutical compositions for the treatment of IL-4 and/or IL-13 mediated signal transduction related disorders |
JP2022519340A (en) * | 2018-12-27 | 2022-03-23 | アケソ・バイオファーマ・インコーポレイテッド | Antibodies to human IL4RA and their use |
RU2700788C1 (en) * | 2019-01-17 | 2019-09-23 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Method for assessment of efficiency of allergen-specific immunotherapy in allergic rhinitis |
WO2020191346A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
WO2021026203A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
JP2023504204A (en) | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | Methods of treating digitally identified IL-4/IL-13 related disorders |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
CN113527485A (en) | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof |
JP2023534024A (en) * | 2020-07-17 | 2023-08-07 | ジーアイ イノベーション, インコーポレイテッド | Fusion protein comprising IGE FC receptor alpha subunit extracellular domain and anti-IL-4 antibody and use of the fusion protein |
JP2024502471A (en) * | 2021-01-08 | 2024-01-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for treating peanut allergy and methods for enhancing peanut allergen-specific immunotherapy by administering an IL-4R antagonist |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
EP0668774A1 (en) | 1991-05-03 | 1995-08-30 | Seragen, Inc. | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
JP3315427B2 (en) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | Dermatitis treatment |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
ZA946875B (en) | 1993-09-07 | 1995-07-06 | Smithkline Beecham Corp | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
US6598603B1 (en) | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
AU766492B2 (en) | 1998-09-18 | 2003-10-16 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
CA2409267C (en) | 2000-05-26 | 2017-02-28 | Immunex Corporation | Interleukin-4 antagonists and compositions thereof |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
KR100572408B1 (en) | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | True Positive Composition and Wound Healing Composition |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
CA2446108A1 (en) | 2001-05-11 | 2002-11-21 | Novartis Ag | Compositions for use in treating ige-associated disorders |
DE60233519D1 (en) | 2001-05-23 | 2009-10-08 | Duotol Ab | SUPPRESSION OF ALLERGIC REACTIONS THROUGH TRANSCUTANEA ADMINISTRATION OF ANYTHING TOGETHER OR MERGED WITH TOXIN UNITS OR THEIR FRAGMENTS |
AU2002357770B2 (en) | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
JP2005530490A (en) | 2002-03-29 | 2005-10-13 | シェーリング コーポレイション | Human monoclonal antibody and method for interleukin-5 and composition comprising the same |
MXPA05005528A (en) | 2002-11-26 | 2006-04-05 | Alk Abello As | Pharmaceutical allergen product. |
JP4764334B2 (en) | 2003-02-01 | 2011-08-31 | タノックス インコーポレーテッド | High affinity anti-human IgE antibody |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
US7638606B2 (en) | 2003-11-07 | 2009-12-29 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
JP2008504806A (en) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | IL-4 / IL-13 specific polypeptides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (en) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | Drug |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (en) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | Head protection airbag device |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
RU2445318C2 (en) | 2006-10-02 | 2012-03-20 | Ридженерон Фармасьютикалз, Инк. | High-affinity human il-4 receptor antibodies |
MX2009010092A (en) | 2007-03-22 | 2010-02-09 | Genentech Inc | Apoptotic anti- ige antibodies binding the membrane-bound ige. |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (en) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergy vaccine formulation for mucosal administration |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
WO2010120524A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
BR112012005117A2 (en) | 2009-09-07 | 2016-05-03 | Dbv Tech | eosinophilic esophagitis treatment method |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
WO2011163614A2 (en) | 2010-06-24 | 2011-12-29 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
PL2624865T3 (en) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
RU2453303C1 (en) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Pharmaceutical composition for atopic dermatitis |
EP2661631A4 (en) | 2011-01-06 | 2014-05-21 | Childrens Hosp Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
WO2012177945A2 (en) | 2011-06-21 | 2012-12-27 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
US20140303067A1 (en) | 2011-10-06 | 2014-10-09 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
ES2701093T3 (en) | 2012-08-21 | 2019-02-20 | Sanofi Biotechnology | Methods to treat or prevent asthma by administering an IL-4R antagonist |
DK2892927T3 (en) | 2012-09-07 | 2018-07-16 | Regeneron Pharma | METHODS OF TREATING ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST |
US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
JP2016507523A (en) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | Bispecific antibodies against CD3ε and BCMA |
TWI755763B (en) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
CA2915839A1 (en) | 2013-06-21 | 2014-12-24 | Leda MANNENT | Methods for treating nasal polyposis by administering an il-4r antagonist |
TWI634900B (en) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
KR20230167770A (en) | 2014-02-21 | 2023-12-11 | 사노피 바이오테크놀로지 | Methods for treating or preventing asthma by administering an il-4r antagonist |
RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
JP6861630B2 (en) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist |
AU2017220184B2 (en) | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
TWI777515B (en) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | Methods of treating eosinophilic esophagitis |
EP3506931A1 (en) | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
KR20230006049A (en) | 2016-09-22 | 2023-01-10 | 리제너론 파아마슈티컬스, 인크. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
IL268349B1 (en) | 2017-02-17 | 2024-04-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
PT3515465T (en) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
EP3703818B1 (en) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
KR20210010518A (en) | 2018-05-13 | 2021-01-27 | 리제너론 파아마슈티컬스, 인크. | How to treat atopic dermatitis by administering an IL-4R inhibitor |
WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
WO2021026203A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
BR112022000377A2 (en) | 2019-08-05 | 2022-05-10 | Regeneron Pharma | Methods for the treatment of atopic dermatitis by administration of an il-4r antagonist |
JP2023504204A (en) | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | Methods of treating digitally identified IL-4/IL-13 related disorders |
EP4153300A1 (en) | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
-
2014
- 2014-05-30 TW TW109120861A patent/TWI755763B/en active
- 2014-05-30 TW TW107126334A patent/TWI697334B/en active
- 2014-05-30 TW TW103118916A patent/TWI633891B/en active
- 2014-06-03 AU AU2014275094A patent/AU2014275094C1/en active Active
- 2014-06-03 CA CA2914203A patent/CA2914203C/en active Active
- 2014-06-03 KR KR1020237002686A patent/KR102580468B1/en active IP Right Grant
- 2014-06-03 ES ES14733922T patent/ES2767080T3/en active Active
- 2014-06-03 WO PCT/US2014/040695 patent/WO2014197470A1/en active Application Filing
- 2014-06-03 CN CN201480032190.3A patent/CN105377894A/en active Pending
- 2014-06-03 SG SG10201913835XA patent/SG10201913835XA/en unknown
- 2014-06-03 JP JP2016518408A patent/JP6499167B2/en active Active
- 2014-06-03 LT LTEP14733922.0T patent/LT3004166T/en unknown
- 2014-06-03 KR KR1020157034008A patent/KR102355114B1/en active Application Filing
- 2014-06-03 MX MX2015016473A patent/MX2015016473A/en unknown
- 2014-06-03 SG SG11201509044QA patent/SG11201509044QA/en unknown
- 2014-06-03 PT PT147339220T patent/PT3004166T/en unknown
- 2014-06-03 EP EP14733922.0A patent/EP3004166B1/en active Active
- 2014-06-03 SI SI201431427T patent/SI3004166T1/en unknown
- 2014-06-03 NZ NZ630183A patent/NZ630183A/en unknown
- 2014-06-03 SG SG10201709670XA patent/SG10201709670XA/en unknown
- 2014-06-03 EP EP19202527.8A patent/EP3617233A1/en active Pending
- 2014-06-03 KR KR1020227001662A patent/KR102492826B1/en active IP Right Grant
- 2014-06-03 RS RS20200093A patent/RS59883B1/en unknown
- 2014-06-03 RU RU2015156628A patent/RU2679920C2/en active
- 2014-06-03 DK DK14733922.0T patent/DK3004166T3/en active
- 2014-06-03 PL PL14733922T patent/PL3004166T3/en unknown
- 2014-06-03 HU HUE14733922A patent/HUE048655T2/en unknown
- 2014-06-03 US US14/294,544 patent/US10392439B2/en active Active
-
2015
- 2015-11-04 ZA ZA2015/08174A patent/ZA201508174B/en unknown
- 2015-11-04 IL IL242456A patent/IL242456B/en active IP Right Grant
- 2015-11-30 MX MX2021002173A patent/MX2021002173A/en unknown
-
2016
- 2016-04-25 HK HK16104712.1A patent/HK1216898A1/en unknown
-
2017
- 2017-12-14 US US15/842,865 patent/US10669341B2/en active Active
- 2017-12-14 US US15/842,868 patent/US10676530B2/en active Active
-
2019
- 2019-03-13 JP JP2019045324A patent/JP6754857B2/en active Active
- 2019-06-27 AU AU2019204577A patent/AU2019204577B2/en active Active
-
2020
- 2020-02-05 HR HRP20200185TT patent/HRP20200185T1/en unknown
- 2020-02-10 CY CY20201100122T patent/CY1124095T1/en unknown
- 2020-03-29 IL IL273678A patent/IL273678A/en unknown
- 2020-04-24 US US16/858,488 patent/US11485788B2/en active Active
- 2020-08-21 JP JP2020139935A patent/JP7061163B2/en active Active
-
2021
- 2021-09-10 AU AU2021229250A patent/AU2021229250A1/en active Pending
-
2022
- 2022-04-14 JP JP2022066688A patent/JP7284313B2/en active Active
- 2022-09-23 US US17/935,003 patent/US20230159647A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081214A patent/JP2023103389A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273678A (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor | |
IL274464A (en) | Compositions and methods for detecting rare sequence variants | |
HK1224140A1 (en) | Inhibitors of transcription factors and uses thereof | |
HK1219947A1 (en) | Carm1 inhibitors and uses thereof carm1 | |
ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
HUE062312T2 (en) | Portable device and method for restricting use of portable device | |
EP3045892A4 (en) | Gas analysis device and gas analysis method | |
EP2972313A4 (en) | Ported parallel plate flow chamber and methods for use thereof | |
EP2967547A4 (en) | Anastomotic device and method | |
HK1223112A1 (en) | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof -tnf-/cxcl10 | |
HK1224307A1 (en) | Protoxin-ii variants and methods of use -ii | |
EP2959712A4 (en) | Method and system for identifying exceptions of people behavior | |
SG2013093067A (en) | Method and system for verification of presence | |
EP2983171A4 (en) | Decoding method and decoding device | |
GB201604534D0 (en) | Nucleic-acid-sequence determination device and nucleic-acid-sequence determination method | |
PL3010620T3 (en) | Filter device and discharge method | |
EP2964225A4 (en) | CaMKII INHIBITORS AND USES THEREOF | |
HK1216754A1 (en) | Anti-rankl antibodies and methods of use -rankl | |
EP3065038A4 (en) | Method for presenting terminal device and terminal device | |
SG11201600347UA (en) | Gas purge device and gas purge method | |
GB201307317D0 (en) | Valve System and Methods of Operation Thereof | |
EP3022205A4 (en) | Novel phosphodiesterase inhibitors and uses thereof | |
PT2769654T (en) | Gas grill and method thereof | |
EP2972012A4 (en) | Compressor device and method | |
GB201315673D0 (en) | Vending apparatus and methods of vending |